Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
C10AX13
|
| gptkbp:CASNumber |
1256937-27-5
|
| gptkbp:developedBy |
gptkb:Amgen
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:evolocumab
|
| gptkbp:hasMolecularFormula |
C7670H11704N2016O2390S52
|
| https://www.w3.org/2000/01/rdf-schema#label |
Repatha
|
| gptkbp:indication |
gptkb:familial_hypercholesterolemia
gptkb:homozygous_familial_hypercholesterolemia cardiovascular disease risk reduction |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:mechanismOfAction |
PCSK9 inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescribes |
adolescents
adults |
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
back pain
injection site reactions upper respiratory tract infection nasopharyngitis |
| gptkbp:target |
gptkb:PCSK9
|
| gptkbp:bfsParent |
gptkb:Amgen
|
| gptkbp:bfsLayer |
6
|